Atreca Inc (OTCPK:BCEL)
$ 0.09 -0.0012 (-1.32%) Market Cap: 3.57 Mil Enterprise Value: -16.54 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Atreca Inc at Canaccord Genuity Growth Conference Transcript

Aug 10, 2022 / 05:30PM GMT
Release Date Price: $2.27 (+5.58%)
John Newman
Canaccord Genuity - Analyst

Good afternoon, everyone. Thank you for joining us for the 42nd annual Canaccord Genuity growth conference. I'm John Newman. I'm one of the Biotech Analysts here at Canaccord. We're very excited to have Atreca with us today, represented by Mr. Tito Serafini, as well as Dr. Jonathan Benjamin. So gentlemen, welcome.

I wondered if we could start by just having you describe the technology developed by Atreca to identify targets and how it's unique in the sector. And to the audience, this might sound like kind of a generic question, but the way that this company has developed technology to identify targets is very, very different from everybody else. So I just wonder if you could tell us a bit about that.

Tito Serafini
Atreca, Inc. - Chief Strategy Officer

Sure. First, thanks very much for inviting us here today. So first, I think, it's the approach that's unique and the unique technology that enables us to execute on that approach. So, we look for new targets, novel targets, and novel epitopes of existing targets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot